C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting

Post time 2024-6-17 17:55:42

journal：Melanoma Research

Authors：Justine Lauwyck; Aline Beckwée; Arno Santens; Julia Katharina Schwarze; Gil Awada; Valérie Vandersleyen; Sandrine Aspeslagh; Bart Neyns

Published date：2021-8-

DOI：10.1097/cmr.0000000000000748

PDF link：https://journals.lww.com/10.1097/CMR.0000000000000748

Article link：http://dx.doi.org/10.1097/cmr.0000000000000748

Article Source：Ovid Technologies (Wolters Kluwer Health)。

Remark：

Post time 2024-6-17 17:55:43

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Ovid] C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Ovid] C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting Copy